Associated Genetic Biomarkers
TYR status serves as an inclusion eligibility criteria in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain TYR status as an inclusion criterion, 3 are phase 1 (3 open).
Trials with TYR status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alteration to serve as an inclusion eligibility criterion is TYR Expression .
Til 1383i t-cell receptor-transduced autologous t-cells and tetravalent rna-lipoplex cancer vaccine are the most frequent therapies in trials with TYR as an inclusion criteria .
Significance of TYR in Diseases
TYR is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain TYR status and melanoma as inclusion criteria, 3 are phase 1 (3 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.